Feb 14 |
Ocuphire Pharma appointed Nirav Jhaveri as CFO
|
Feb 14 |
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
|
Feb 5 |
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
|
Jan 24 |
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jan 10 |
Ocuphire Pharma files for a $175M mixed securities shelf
|
Jan 4 |
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
|
Dec 5 |
Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)
|
Nov 30 |
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
|
Nov 27 |
Ocuphire announces appointment of Joseph Schachle as chief operating officer
|
Nov 27 |
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
|